Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer

被引:8
作者
White, Abby A. [1 ]
Lee, Daniel N. [1 ]
Mazzola, Emanuele [2 ]
Kucukak, Suden [1 ]
Polhemus, Emily [1 ]
Jaklitsch, Michael T. [1 ]
Mentzer, Steven J. [1 ]
Wee, Jon O. [1 ]
Bueno, Raphael [1 ]
Swanson, Scott J. [1 ]
机构
[1] Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Div Biostat, Dept Data Sci, Boston, MA USA
关键词
single‐ station; triple therapy; VATS; STAGE; CHEMOTHERAPY;
D O I
10.1002/jso.26305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The purpose of this study was to evaluate treatment strategies and factors influencing overall survival (OS) and disease-free survival (DFS) in resectable, non-small cell lung cancer (NSCLC) with mediastinal (N2) lymph node metastasis. Methods All patients undergoing surgery for NSCLC with N2 disease between 2006 and 2016 were included. Treatment approaches included surgery only, neoadjuvant therapy followed by surgery, surgery followed by adjuvant therapy, and neoadjuvant therapy followed by surgery and adjuvant therapy (triple therapy). Patient clinical and pathologic data were retrospectively collected. Results A total of 281 patients were included in the study. In total, 209 patients had neoadjuvant therapy, 47.4% of which went on to received additional adjuvant therapy. The pathologic complete response rate was 12.9%. The treatment strategy which included triple therapy was isolated as a significant contributor to improved OS and DFS. Nodal downstaging (N0) after induction therapy conferred an OS benefit (38.3% vs. 15.6%, p = .03). Patients with single-station N2 disease experienced higher DFS. Video-assisted thoracic surgery (VATS) lobectomy completion rates were higher at the end of the study period compared to the beginning (p < .001). Conclusions Patients who undergo neoadjuvant therapy for N2-positive NSCLC may benefit from additional adjuvant therapy. Single-station N2 disease confers higher DFS. VATS completion rates for lobectomy increase as experience increases.
引用
收藏
页码:579 / 586
页数:8
相关论文
共 10 条
  • [1] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [2] The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
    Amini, Arya
    Correa, Arlene M.
    Komaki, Ritsuko
    Chang, Joe Y.
    Tsao, Anne S.
    Roth, Jack A.
    Swisher, Stephen G.
    Rice, David C.
    Vaporciyan, Ara A.
    Lin, Steven H.
    [J]. ANNALS OF THORACIC SURGERY, 2012, 94 (03) : 914 - 921
  • [3] Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications
    Andre, F
    Grunenwald, D
    Pignon, JP
    Dujon, A
    Pujol, JL
    Brichon, PY
    Brouchet, L
    Quoix, E
    Westeel, V
    Le Chevalier, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2981 - 2989
  • [4] [Anonymous], 2018, SURV EP END RES SEER
  • [5] Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival
    Bueno, R
    Richards, WG
    Swanson, SJ
    Jaklitsch, MT
    Lukanich, JM
    Mentzer, SJ
    Sugarbaker, DJ
    [J]. ANNALS OF THORACIC SURGERY, 2000, 70 (06) : 1826 - 1831
  • [6] Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935
    Jaklitsch, Michael T.
    Herndon, James E., II
    Decamp, Malcolm M., Jr.
    Richards, William G.
    Kumar, Parvesh
    Krasna, Mark J.
    Green, Mark R.
    Sugarbaker, David J.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (07) : 599 - 606
  • [7] A tutorial on propensity score estimation for multiple treatments using generalized boosted models
    McCaffrey, Daniel F.
    Griffin, Beth Ann
    Almirall, Daniel
    Slaughter, Mary Ellen
    Ramchand, Rajeev
    Burgette, Lane F.
    [J]. STATISTICS IN MEDICINE, 2013, 32 (19) : 3388 - 3414
  • [8] A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    ROSELL, R
    GOMEZCODINA, J
    CAMPS, C
    MAESTRE, J
    PADILLE, J
    CANTO, A
    MATE, JL
    LI, SR
    ROIG, J
    OLAZABAL, A
    CANELA, M
    ARIZA, A
    SKACEL, Z
    MORERAPRAT, J
    ABAD, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (03) : 153 - 158
  • [9] A RANDOMIZED TRIAL COMPARING PERIOPERATIVE CHEMOTHERAPY AND SURGERY WITH SURGERY ALONE IN RESECTABLE STAGE IIIA NON-SMALL-CELL LUNG-CANCER
    ROTH, JA
    FOSSELLA, F
    KOMAKI, R
    RYAN, MB
    PUTNAM, JB
    LEE, JS
    DHINGRA, H
    DECARO, L
    CHASEN, M
    MCGAVRAN, M
    ATKINSON, EN
    HONG, WK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (09) : 673 - 680
  • [10] Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigms
    Spicer, Jonathan D.
    Shewale, Jitesh B.
    Nelson, David B.
    Mitchell, Kyle G.
    Bott, Matthew J.
    Vallieres, Eric
    Wilshire, Candice L.
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Jones, David R.
    Darling, Gail E.
    Sepesi, Boris
    [J]. ANNALS OF THORACIC SURGERY, 2019, 107 (01) : 277 - 284